NewAmsterdam Pharma Company NV Total Current Liabilities

NewAmsterdam Pharma Company NV (NAMS) currently reports a total current liabilities of $67M as of March 2026. That compares with $41M in the prior-year period — up 64.8% year over year. Use the charts on this page to explore NewAmsterdam Pharma Company NV's total current liabilities history and peer comparisons.

NewAmsterdam Pharma Company NV's total current liabilities increased from $41M to $67M — a 64.8% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

NewAmsterdam Pharma Company NV reported $67M in total current liabilities as of March 2026. That compares with $41M in the prior-year period — up 64.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $67M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for NewAmsterdam Pharma Company NV, and consider following NAMS for alerts when major investors trade the stock.